We are live on ! Find out more
PCRX icon

Pacira BioSciences
PCRX

276 hedge funds and large institutions have $3.04B invested in Pacira BioSciences in 2021 Q4 according to their latest regulatory filings, with 46 funds opening new positions, 105 increasing their positions, 82 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

77% more first-time investments, than exits

New positions opened: 46 | Existing positions closed: 26

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

28% more repeat investments, than reductions

Existing positions increased: 105 | Existing positions reduced: 82

11% more capital invested

Capital invested by funds: $2.75B → $3.04B (+$298M)

7% more funds holding

Funds holding: 259 → 276 (+17)

3.11% more ownership

Funds ownership: 110.52% → 113.63% (+3.1%)

67% less call options, than puts

Call options by funds: $1.67M | Put options by funds: $5.08M

Holders
276
Holders Change
+17
Holders Change %
+6.56%
% of All Funds
4.25%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.06%
New
46
Increased
105
Reduced
82
Closed
26
Calls
$1.67M
Puts
$5.08M
Net Calls
-$3.42M
Net Calls Change
-$7.42M

Top Buyers

Rank Fund Capital Flow
1
PC
Paulson & Co
New York
+$24.6M
2
AC
Armistice Capital
New York
+$20.7M
3
Baillie Gifford & Co
Baillie Gifford & Co
United Kingdom
+$14.7M
4
Marshall Wace
Marshall Wace
United Kingdom
+$10.5M
5
HCM
Hodges Capital Management
Texas
+$9.26M

Top Sellers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
-$20.5M
2
Wells Fargo
Wells Fargo
California
-$18M
3
NPIC
Neumeier Poma Investment Counsel
California
-$16.2M
4
Goldman Sachs
Goldman Sachs
New York
-$14.3M
5
TA
Tamarack Advisers
California
-$7.44M
Name Holding Trade Value Shares
Change 		Change in
Stake
PP
276
PDT Partners
New York
– -$714K -12,743 Closed
DA
277
Duality Advisers
Florida
– -$560K -10,000 Closed
BCM
278
Bridgeway Capital Management
Texas
– -$465K -8,300 Closed
LFAS
279
Level Four Advisory Services
Texas
– -$439K -7,846 Closed
CC
280
Centiva Capital
New York
– -$417K -7,461 Closed
WG
281
Winton Group
United Kingdom
– -$416K -7,437 Closed
VRS
282
Virginia Retirement Systems
Virginia
– -$381K -6,800 Closed
BAM
283
Blueshift Asset Management
New Jersey
– -$376K -6,710 Closed
MYIA
284
Mount Yale Investment Advisors
Colorado
– -$224K -4,005 Closed
PCM
285
Penserra Capital Management
California
– -$57K -1,020 Closed
HI
286
Harbour Investments
Wisconsin
– -$39K -695 Closed
GRP
287
Global Retirement Partners
California
– -$20K -350 Closed
LWM
288
Liberty Wealth Management
California
– -$8K -142 Closed
APWA
289
Atlas Private Wealth Advisors
New Jersey
– -$6K -100 Closed
SWM
290
Spire Wealth Management
Virginia
– -$6K -100 Closed
DFCM
291
Dark Forest Capital Management
Puerto Rico
– -$4.03K -73 -91%
CFA
292
Cahill Financial Advisors
Minnesota
– -$4K -66 Closed
CI
293
Cordant Inc
Oregon
– -$1K -16 Closed
ACM
294
Anfield Capital Management
California
– -$1K -11 Closed
JFGIW
295
Johnson Financial Group Inc (Wisconsin)
Wisconsin
– -$165 -3 -50%
RFA
296
Reilly Financial Advisors
California
– +$276 +5 New
SC
297
Schubert & Co
Texas
– +$276 +5 New
JWA
298
JFS Wealth Advisors
Pennsylvania
– +$331 +6 New
8 9 10 11
12

PCRX Hedge Fund Activity: Q4 2021 in Review

276 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q4 2021, worth a combined $3.04B — up 11% from $2.75B a quarter earlier.

Buyers outnumbered sellers: 46 funds opened new PCRX positions and 26 closed out — a net gain of 20 holders — while 105 added to existing stakes and 82 trimmed.

The largest buyer was Paulson & Co, adding an estimated $24.6M. The largest seller was Deerfield Management, cutting an estimated $20.5M.

  • 276 institutional investors held Pacira BioSciences (PCRX) as of Q4 2021, up from 259 in Q3 2021.
  • Funds reported $3.04B of Pacira BioSciences stock for Q4 2021, up 11% quarter-over-quarter.
  • 46 funds opened new Pacira BioSciences positions in Q4 2021 and 26 closed out, a net change of +20 holders.
  • The largest Pacira BioSciences buyer in Q4 2021 was Paulson & Co, an estimated $24.6M added.
  • The largest Pacira BioSciences seller in Q4 2021 was Deerfield Management, an estimated $20.5M sold.

Based on aggregated 13F filings for Q4 2021.